CN105431166B - 结核病组合物和其使用方法 - Google Patents

结核病组合物和其使用方法 Download PDF

Info

Publication number
CN105431166B
CN105431166B CN201480040735.5A CN201480040735A CN105431166B CN 105431166 B CN105431166 B CN 105431166B CN 201480040735 A CN201480040735 A CN 201480040735A CN 105431166 B CN105431166 B CN 105431166B
Authority
CN
China
Prior art keywords
mtb
antigen
antigens
mtb antigen
latent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480040735.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105431166A (zh
Inventor
拉维·安纳萨
娜塔莉·卡提欧
托马斯·G·埃文斯
米歇尔·斯通
巴里·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Aids Vaccine Action Corp
Original Assignee
International Aids Vaccine Action Corp
International AIDS Vaccine Initiative Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Aids Vaccine Action Corp, International AIDS Vaccine Initiative Inc filed Critical International Aids Vaccine Action Corp
Publication of CN105431166A publication Critical patent/CN105431166A/zh
Application granted granted Critical
Publication of CN105431166B publication Critical patent/CN105431166B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480040735.5A 2013-06-25 2014-06-24 结核病组合物和其使用方法 Active CN105431166B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838872P 2013-06-25 2013-06-25
US61/838,872 2013-06-25
PCT/US2014/043889 WO2014210018A1 (en) 2013-06-25 2014-06-24 Tuberculosis compositions and methods of using the same

Publications (2)

Publication Number Publication Date
CN105431166A CN105431166A (zh) 2016-03-23
CN105431166B true CN105431166B (zh) 2020-09-18

Family

ID=52111114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480040735.5A Active CN105431166B (zh) 2013-06-25 2014-06-24 结核病组合物和其使用方法

Country Status (7)

Country Link
US (4) US10266574B2 (enExample)
EP (2) EP3013364B1 (enExample)
JP (2) JP6554095B2 (enExample)
CN (1) CN105431166B (enExample)
ES (1) ES2925950T3 (enExample)
WO (1) WO2014210018A1 (enExample)
ZA (1) ZA201509262B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2872172B1 (en) * 2012-07-10 2018-11-14 Transgene SA Mycobacterial antigen vaccine
CN105431166B (zh) * 2013-06-25 2020-09-18 国际艾滋病疫苗行动组织公司 结核病组合物和其使用方法
CA2936131A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
WO2016120489A2 (en) * 2015-02-01 2016-08-04 Theravectys Lentiviral vectors for expression of mycobacterium tuberculosis antigens
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
CN108239660B (zh) * 2016-12-26 2021-08-10 上海生物制品研究所有限责任公司 一种重组结核病疫苗，其制备方法及应用
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes
KR102135334B1 (ko) * 2018-12-19 2020-07-17 대한민국 결핵 다가 항원을 발현하는 재조합 아데노 바이러스 및 이를 포함하는 결핵 예방용 조성물
CN116327906A (zh) * 2021-12-22 2023-06-27 中国人民解放军总医院第八医学中心 一种结核分枝杆菌串联dna疫苗w545及其制备方法与应用
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
WO1994016737A1 (en) 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
KR101329323B1 (ko) 2004-12-01 2013-11-14 아에라스 글로벌 티비 백신 파운데이션 엔도솜을 이탈하는 능력이 보강된 재조합 비씨지 균주
AU2006261445B2 (en) 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
BRPI0620693A2 (pt) * 2005-12-15 2016-12-13 Aeras Global Tb Vaccine Found método para suscitar uma resposta imune tanto sistêmica como de mucosa a mycobacteria viva atenuada ou antígenos micobacterianos em um hospedeiro
JP5378350B2 (ja) * 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
US8361482B2 (en) 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
CN101289496B (zh) 2008-05-30 2011-06-29 中国医学科学院医学生物学研究所 能激发机体抗结核杆菌的保护性免疫反应的抗原表位筛选方法及用途
JP5690814B2 (ja) 2009-04-28 2015-03-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 抗原特異的な免疫応答を高めるための組成物及び方法
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
KR20120139657A (ko) 2009-11-02 2012-12-27 고쿠리츠다이가쿠호진 미에다이가쿠 파라믹소바이러스 벡터를 사용한 비강내 분무형 결핵 백신
US8932600B2 (en) 2010-01-27 2015-01-13 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
US20120003256A1 (en) 2010-03-01 2012-01-05 Huiling Han Tuberculosis antigens, immunogenic compositions, diagnostics and methods related to the same
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
EP2872172B1 (en) * 2012-07-10 2018-11-14 Transgene SA Mycobacterial antigen vaccine
CN105431166B (zh) 2013-06-25 2020-09-18 国际艾滋病疫苗行动组织公司 结核病组合物和其使用方法
CN104474538A (zh) 2014-08-13 2015-04-01 华中科技大学 一种重组卡介苗

Also Published As

Publication number Publication date
EP3013364B1 (en) 2022-08-03
WO2014210018A1 (en) 2014-12-31
US20140377300A1 (en) 2014-12-25
JP2016529223A (ja) 2016-09-23
US20210371474A1 (en) 2021-12-02
US20240101612A1 (en) 2024-03-28
US11014969B2 (en) 2021-05-25
ES2925950T3 (es) 2022-10-20
ZA201509262B (en) 2017-11-29
US10266574B2 (en) 2019-04-23
JP2019187441A (ja) 2019-10-31
EP3013364A4 (en) 2017-05-31
US20190322709A1 (en) 2019-10-24
JP6554095B2 (ja) 2019-07-31
CN105431166A (zh) 2016-03-23
EP3013364A1 (en) 2016-05-04
US11787842B2 (en) 2023-10-17
JP7269806B2 (ja) 2023-05-09
EP4176897A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
US11787842B2 (en) Tuberculosis compositions and methods of using the same
US20230365631A1 (en) Tuberculosis Compositions And Methods Of Treating Or Preventing Tuberculosis
KR101942372B1 (ko) B형 간염 바이러스 코어 단백질을 암호화하는 핵산 분자 및 이를 포함하는 백신
US12168047B2 (en) Tuberculosis antigen cassettes
US10953079B2 (en) Synthetic immunogens for prophylaxis or treatment of tuberculosis
JP2019142947A (ja) ボツリヌス菌の各血清型の重鎖を使用する１価または多価のボツリヌス神経毒素ワクチン

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American Maryland

Applicant after: Aeras Foundation

Address before: American Maryland

Applicant before: International AIDS Vaccine Initiative, Inc.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190805

Address after: American New York

Applicant after: International AIDS Vaccine Action Corp.

Address before: American Maryland

Applicant before: Aeras Foundation

GR01 Patent grant
GR01 Patent grant